title: Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
abstract: BACKGROUND
  Women with ovarian cancer who experience disease progression during or within 6 months of first-line treatment with platinum-based anticancer drugs are considered to have platinum-resistant tumors. These patients have an unfavorable prognosis, and they frequently seek complementary and alternative therapies (CAM). Historically, this represents an understudied and underreported component of ovarian cancer treatment.
  
  
  METHODS
  This report describes the case of a woman with rapidly progressive, platinum-resistant ovarian cancer. Upon initiating self-directed treatment with Haelan951, a commercially available fermented soy beverage, she entered into a phase of prolonged disease stabilization including improvement in the serum tumor marker CA-125.
  
  
  CONCLUSIONS
  Fermented soy products are known to contain high concentrations of the isoflavone, genistein, and other compounds that exhibit anticancer activity in preclinical models. This case report supports the prospective evaluation of alternative therapies such as these in patients with platinum-refractory ovarian cancer.
authors.affiliation: Division of Medical Oncology, Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, MA 02114, USA.
authors.forename: Amber
authors.initials: A
authors.lastname: Klein
authors.forename: Xiaoying
authors.initials: X
authors.lastname: He
authors.forename: Maria
authors.initials: M
authors.lastname: Roche
authors.forename: Allison
authors.initials: A
authors.lastname: Mallett
authors.forename: Linda
authors.initials: L
authors.lastname: Duska
authors.forename: Jeffrey G
authors.initials: JG
authors.lastname: Supko
authors.forename: Michael V
authors.initials: MV
authors.lastname: Seiden
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D000529:Complementary Therapies / Q000379:methods*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D019833:Genistein / Q000032:analysis / Q000097:blood; D020719:Glucuronides / Q000097:blood; D006801:Humans; D007529:Isoflavones / Q000032:analysis; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D041942:Soy Milk / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D019772:Topotecan / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D020719:Glucuronides; D007529:Isoflavones; D003841:Deoxycytidine; C004742:daidzein; D019772:Topotecan; D004317:Doxorubicin; D016190:Carboplatin; D019833:Genistein; D017239:Paclitaxel; D000093542:Gemcitabine